FDA official: US AstraZeneca stockpile not in danger of expiring
While Europe simultaneously wrestles with national vaccine suspensions and AstraZeneca’s own delivery shortages, the US is still sitting on a pile of tens of millions of doses. They aren’t going anywhere, and a top health official Wednesday said they’re not in danger of expiring.
“I do not believe we are at risk of throwing this out at any time in the near future,” Peter Marks, the director of the Food and Drug Administration’s vaccine center, told a House panel.
The federal government preordered 300 million doses of the vaccine under the Trump administration, but issues with clinical trials have held up its authorization and the FDA is still waiting on additional data.
Officials have said the stockpile is intended to make it easier to quickly distribute the vaccine across the country if the company receives FDA clearance in the coming weeks.